In this episode, David Flores engages in a conversation with Brett Waters, Esq., the Co-Founder and Executive Director of Reason for Hope, to explore policy and legal reforms aimed at realizing safe, ethical, and affordable access to psychedelic-assisted therapy.
In this interview, Psychedelic Spotlight’s Swati Sharma and Fireside Co-Founder…
Psychedelic Spotlight Interview with Douglas K. Gordon In this episode…
In this episode of the Psychedelic Spotlight Podcast, our Director of Content catches up with Christi Myers, founder and director of Flow Wellness. Christi discusses her career as a paramedic and how that translates into her work now, helping people heal traumas with ketamine therapy.
In our previous video, we discussed the upcoming IPO of Horizons Psychedelic ETF (PSYK).
Recently, on January 27th, PSYK began trading on the Canadian NEO Stock Exchange.
In this episode we are going to discuss the psychedelic ETF and what it means for MindMed, NUMI, Compass Pathways and other stocks in the psychedelic sector.
We will cover a few things such as:
– PSYK’s fundamentals
– PSYK’s CEO Steve Hawkins
-Is Horizons ETF actively or passively managed?
– What psychedelic stocks are included in the ETF?
– How often does th ETF reorganize its stock holdings?
– How is the size of the individual stocks’ position decided on?
– Is it worth investing in PSYK now?
– What will happen to MindMed (MMED/MMEDF), Numinus Wellness (NUMI), Compass Pathways (CMPS) and the other stocks once they are included?
***A quick reminder, the psychedelic sector is at a VERY early stage, and all of these companies, large-cap and small cap alike, will need to attract more funding to complete their clinical trials and bring their products to market. PSYK will however contribute to this sector as it will bring more funding to the industry as a whole, which will both help individual companies and the wider mission of treating mental health disorders.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#PSYK #MindMed #MMED
![LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-35-600x338.jpeg)
Hey Psychedelic Investors, today we are actually going to have two episodes, one to present the news updates, and then a second one, which will take place in the Speculation Zone to discuss why these may be super important
So make sure you stick around for both.
Timecodes:
0:00 – Intro
3:30 – New Phase 1 Clinical Trial
9:45 – Changes in Leadership
13:19 – New MindMed Partnership
20:30 – Conclusion
So what is the latest MindMed news and what does it mean for the future of MMED/MMEDF?
First up, we have news from the end of January that MindMed has started their phase one clinical trial combining MDMA with LSD.
Why combine these two substances?
What diseases could it help alleviate?
And what is the timeline for this project?
Next we will cover MindMed’s change in leadership structure. A CEO has stepped down, does this mean we are seeing a game of thrones in the boardroom? Well… no. It’s actually much more practical than that.
Here we will cover: Why did they do this, and how will it affect MMED/MMEDF going forward, specifically with MindMed ‘s Nasdaq Uplisting application.
Finally, and most importantly, we will talk about how MindMed is further expanding their development pipeline and IP portfolio through a partnership with a Swiss company called MindShift Compounds. This is very exciting as it ads to MindMed’s ever expanding clinical trial pipeline.
Pretty soon it’s going to be hard keeping track of all of MindMed’s projects.
Hey there guys so before we begin the episode I just want to let you know that I was just interviewed on the channel The Medicine of being Human.
We talked about all sorts of interesting topics and I had a great time.
I am not sure if by the time this video is released, if the interview will already be out, but ill put a link in the description to the Channel, and also to Sena’s Instagram page.
https://www.youtube.com/channel/UChW422KBFaEfB9DJG_cKySQ
https://www.instagram.com/sena__maria/
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video from Pexels
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDF #MindmedStock
Join David in this engaging episode as he converses with Kimberly Carlson, CEO & CFO of Mushrooms Inc., a pioneering company at the forefront of driving sustainable practices through innovative mycelium applications.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
